BASi Strengthens Preclinical PK/PD Leadership With the Hiring of James E. Burleigh as Director of Operations, Preclinical PK/PD
WEST LAFAYETTE, Ind., September 19, 2017 (Newswire.com) - Bioanalytical Systems, Inc. (NASDAQ:BASI) ("BASi" or the "Company") today announced the addition of James E. Burleigh as Director of Operations, Preclinical PK/PD.
"With his vast experience and impeccable reputation, we are incredibly pleased to have Jim Burleigh join the BASi team," said Philip A. Downing, Senior Vice President of Preclinical Services. "Having worked for BASi before, Jim is very familiar with the company's processes and objectives and is prepared to hit the ground running to optimize our Preclinical PK/PD operations. Jim is known for his collegiality, dependability and calm demeanor, making him the perfect anchor for leading and mentoring this team for ongoing success. His appointment represents yet another important step for BASi as we seek to further expand our preclinical capabilities and build on an already exemplary track record of supporting our clients' drug discovery and preclinical development efforts."
Mr. Burleigh will lead BASi's Preclinical PK/PD Laboratory reporting to Philip A. Downing, Senior Vice President of Preclinical Services. Mr. Burleigh's responsibilities will include, among others, directing DMPK studies in BASi's state-of-the-art vivarium using their Culex® in vivo sampling systems, leveraging his experience in pharmacokinetics and IACUC, operations and administration oversight, while driving continuous improvement in quality and financial performance.
It's great to welcome back one of our most innovative preclinical research leaders as we add to our services to validate drug leads on their way to the clinic.
BASi founder and scientific adviser Peter Kissinger commented, "It's great to welcome back one of our most innovative preclinical research leaders as we add to our services to validate drug leads on their way to the clinic."
Mr. James Burleigh earned his B.S. in Zoology from Michigan State University in 1979. Mr. Burleigh has several years' ascendant experience in scientist roles with Pfizer Global Research and Development (formerly Parke-Davis) from 1984-2002. As Director of In Vivo for BASi from 2003-2007, Mr. Burleigh developed, managed and directed facility operations in a new vivarium, and incorporated changes to transform the facility into a USDA regulatory environment. He also co-developed a novel, automated bile collection system for rats. As Sr. Research Scientist II for Wyeth Research (Pfizer) from 2007-2010, Mr. Burleigh served as IACUC liaison and managed discovery and development study coordination, new model development, and automated blood sampling. Mr. Burleigh's most recent role was Associate Director, DMPK for Frontage Laboratories where he was responsible for in-life laboratory process, development and management.
About Bioanalytical Systems, Inc.
BASi is a pharmaceutical development company providing Preclinical, Toxicological and Bioanalytical contract research services and monitoring instruments to the world's leading drug development companies and medical research organizations. The Company's in vivo automated sampling center is a purpose-built facility including ten in vivo labs, colony rooms for rats and mice with individually ventilated housing systems (IVCs), rodent surgical site, and a wet lab and cage wash facility that is complemented by state-of-the-art cold storage, formulations and bioanalytical facilities. The Company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit www.BASinc.com for more information about BASi.
This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company's filings with the Securities and Exchange Commission.
Chief Financial Officer &
Vice President of Finance
Source: Bioanalytical Systems, Inc.